Synthesis of the tolerance-inducing oligosaccharide lacto-N-fucopentaose III bearing an activated linker

Article abstract of DOI:10.1002/open.201300024

A concise synthetic route to an immunomodulatory pentasaccharide, lacto-N-fucopentaose III (1) and its corresponding human serum albumin conjugate, is described. Key transformations of the strategy include two highly regio- and stereoselective glycosylations for the construction of disaccharide 10 and pentasaccharide 12, a Birch reduction for deprotection of benzyl ethers, and a UV-promoted radical addition of a thiol to an alkene for modification of the aglycone.

Full text of DOI:10.1002/open.201300024

DOI: 10.1002/open.201300024
Synthesis of the Tolerance-Inducing Oligosaccharide Lacto-
N-Fucopentaose III Bearing an Activated Linker
Junfeng Zhang, Lu Zou, and Todd L. Lowary*[a]
A concise synthetic route to an immunomodulatory penta-
saccharide, lacto-N-fucopentaose III (1) and its corresponding
human serum albumin conjugate, is described. Key transforma-
tions of the strategy include two highly regio- and stereoselec-
tive glycosylations for the construction of disaccharide 10 and
pentasaccharide 12, a Birch reduction for deprotection of
benzyl ethers, and a UV-promoted radical addition of a thiol to
an alkene for modification of the aglycone.
Introduction
Lacto-N-fucopentaose III (LNFPIII), a pentasaccharide containing
the LewisX trisaccharide antigen, is an immunomodulatory
glycan that is present on schistosome eggs.[1] The expression
of LNFPIII on schistosome eggs has been shown to suppress
host immune responses, which enables the parasite to escape
detection of the mammalian host immune system thus facili-
tating survival.[1] LNFPIII is also found in breast milk and the
urine of pregnant women, as well as the fetal brain, and has
been speculated to have a similar protective immunomodula-
tory effect in the fetus.[1,2] Recently, Burlingham and co-workers
demonstrated that a LNFPIII conjugate can prolong allogeneic
graft survival in neonatal heart transplantation models.[3] Al-
though the biological role LNFPIII plays in graft prolongation
remains to be further investigated, a preliminary mechanistic
study suggested that the LNFPIII conjugate significantly upre-
gulated the expression of programmed death ligand 1,[3] which
negatively regulates immune responses through binding with
its receptor, programmed cell death protein 1, expressed on
the surface of activated Tcells, B cells and macrophages.[4] This
observation suggests that LNFPIII is a potential tolerance-
inducing oligosaccharide.
promote immune tolerance to these antigens in neonates. Car-
rying out these studies required access to milligram quantities
of LNPFIII functionalized with a linker that would allow its at-
tachment to surfaces, for example, proteins as well as amine-
coated nanoparticles or stents.[6] Although previous synthesis
of LNPFIII derivatives have been reported by Sinay¨[7] and
Zhang,[8] none of these compounds was suitably functionalized
for our purposes. We describe here the synthesis of LNPFIII
bearing an activated ester moiety in the aglycone 1 (Figure 1)
and its corresponding human serum albumin (HSA) conjugate.
Results and Discussion
We envisioned (Scheme 1) constructing pentasaccharide 1
from four readily available carbohydrates, d-galactose, l-fu-
cose, N-acetyl-d-glucosamine and lactose, via trisaccharide
thioglycoside 2 and disaccharide diol 3. An important feature
was a regio- and stereoselective [3+2] glycosylation, a key
strategy in earlier routes to LNPFIII derivatives,[7,8] followed by
global deprotection and introduction of the activated ester.
Thioglycoside 2 can be assembled through regioselective con-
densation of trichloroacetimidate 4 with diol 6 followed by
treatment of the product with thioglycoside 5.
We have been interested in accessing devices (nanoparticles
or stents) carrying synthetic ABO blood group antigens and
tolerance-inducing glycans for use in inducing specific B-cell
tolerance during immune development, with the aim to
extend the window for ABO-incompatible heart transplants.[5]
As part of this program, we wanted to determine if LNFPIII pre-
sented together with the ABO blood group structures could
As illustrated in Scheme 2, diol 3 was prepared from lactose.
First, acetylation was performed in acetic anhydride at 1008C
in the presence of sodium acetate to form preferentially the
b anomer of lactose heptaacetate (a/b=1:5). This compound
was then coupled with 7-octen-1-ol using boron trifluoride di-
ethyl etherate as the promoter to generate octenyl glycoside 7
1
[a] J. Zhang, L. Zou, T. L. Lowary
in 43% overall yield. The H NMR spectrum of 7 showed the
Alberta Glycomics Centre and Department of Chemistry
University of Alberta, Gunning-Lemieux Chemistry Centre
Edmonton, AB T6G 2G2 (Canada)
anomeric proton H-1 at 4.45 ppm as a doublet with a coupling
constant between H-1 and H-2 of 8.0 Hz, indicating the newly
formed glycosidic linkage was b. Then, deacetylation of 7
using a catalytic amount of sodium methoxide afforded 8 in
92% yield. Finally, installation of an isopropylidene ketal at the
3’- and 4’-positions of 8, benzylation of the remaining five hy-
droxyl groups, followed by acid hydrolysis of the isopropyli-
dene ketal enabled the conversion of 8 to diol 3 in 63% yield
over three steps.[9] To access diol 6, previously reported com-
E-mail: tlowary@ualberta.ca
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/open.201300024.
ꢀ 2013 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly
cited and is not used for commercial purposes.
ꢀ 2013 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ChemistryOpen 2013, 2, 156 – 163 156

www.chemistryopen.org
Figure 1. Structure of LNPFIII 1 with activated flexible linker.
reochemistry was confirmed
from the H-1, H-2 coupling con-
stant of the galactopyranosyl
residue (3JHꢀ1,Hꢀ2 =8.0 Hz). The
regioselectivity of the glycosyla-
tion was determined by a 2D
NMR experiment. In the HMBC
spectrum of 10, the expected
correlations between H-1Gal and
C-4GlcNAc, H-4GlcNAc and C-1Gal are
both observed, while correla-
tions between H-1Gal and C-
3GlcNAc, H-3GlcNAc and C-1Gal are
not, indicating that the newly
Scheme 1. Retrosynthetic analysis of 1. Bn=benzyl; Phth=phthaloyl; Tol=tolyl.
formed glycosidic linkage is the
desired b-(1!4)-linked disac-
charide instead of the b-(1!3)-
linked isomer. The regioselectivity of this glycosyla-
tion can be rationalized by matched–mismatched
glycosylation.[13,14] In this case, disarmed donor 4
reacts preferentially with the less reactive C-4 hydrox-
yl group in diol 6. In addition, the steric effect in-
duced by the
N-phthalimido group at C-2 position also likely con-
tributes to the regioselectivity.[13]
The fucosylation of disaccharide 10 with thioglyco-
side 5 in toluene using N-iodosuccinimide (NIS) and
silver triflate (AgOTf) as the catalyst provided trisac-
charide 2 in 75% yield with excellent stereoselectiv-
ity. The anomeric proton of the fucopyranoside resi-
due in 10 appeared around 4.84 ppm, overlapping
with a methylene proton from the benzyl groups.
Therefore, the one-bond heteronuclear coupling con-
Scheme 2. Synthesis of building blocks A) 3 and B) 6. Reagents and conditions: a) Ac2O,
NaOAc, 1008C, 79%; b) BF3·Et2O, 7-octen-1-ol, CH2Cl2, 43%; c) NaOMe, 1:3 v/v CH2Cl2/
MeOH, RT, overnight, 92%; d) (CH3)2C(OCH3)2, p-TsOH, DMF, 858C, 1.5 h; e) NaH
(6.6 equiv), BnBr (8.3 equiv), DMF, 08C!RT; f) 4:1 v/v AcOH/H2O, 808C, 3 h, 63% over
three steps; g) BH3·NMe3 (4.0 equiv), AlCl3 (6.0 equiv), THF, RT, 3 h, 83%.
stant at the anomeric centre of the fucose residue
[15]
(1JCꢀ1,Hꢀ1
)
was used to determine the stereochemis-
try at the newly formed linkage; the value is
170.3 Hz, which unambiguously confirms the a ste-
reochemistry of this residue. The armed nature of 5
relative to 10[10] allows this reaction to proceed effi-
pound 9[10] underwent regioselective reductive opening of the
ciently without competing activation of the disaccharide ac-
ceptor or trisaccharide product.
[11]
benzylidene ring using BH3·NMe3 and AlCl3 to the desired
compound in 82% yield. Building blocks 4[12] and 5[10] and
were synthesized according to previous reports.
The final planned glycosylation reaction, coupling of trisac-
charide 2 and diol 3, cannot be carried out using NIS and
AgOTf activation because of incompatibility of these condi-
tions with the alkene functionality in the aglycone. To circum-
vent this problem, an alternative promoter system using di-
phenylsulfoxide in combination with triflic anhydride[16] was ex-
plored, but the desired product was obtained in low yield. Al-
With 3–6 in hand, the construction of the pentasaccharide
was carried out (Scheme 3). First, trichloroacetimidate 4 was
coupled with diol 6 in the presence of trimethylsilyl
trifluoromethanesulfonate (TMSOTf) to generate regioselective-
ly the b-(1!4)-linked disaccharide 10 in 70% yield. The b ste-
ꢀ 2013 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ChemistryOpen 2013, 2, 156 – 163 157

www.chemistryopen.org
With the pentasaccharide as-
sembled, treatment of 12 with
ethylenediamine in n-butanol at
1008C for 20 h (Scheme 4), fol-
lowed by selective N-acetylation,
led to formation of 13. Birch re-
duction was conducted to
remove the benzyl groups, while
keeping intact the alkene func-
tionality for further modification.
The fully unprotected pentasac-
charide 14 was obtained in 97%
yield. A UV-promoted radical ad-
dition of a thiol to the alkene[17]
was then performed to further
functionalize the octenyl linker
with a cysteamine residue, lead-
ing to corresponding amine
salt 15 in quantitative yield. Fi-
nally, the amine salt was con-
Scheme 3. Synthesis of protected pentasaccharide 12. Reagents and conditions: a) TMSOTf, CH2Cl2, ꢀ408C, 2 h
70%; b) 5 (2.5 equiv), NIS (2.4 equiv), AgOTf (0.24 equiv), toluene, 08C, 75%; c) NBS (2.5 equiv), 9:1 v/v acetone/
H2O, 08C, 0.5 h, 80%; d) DBU, Cl3CCN (7.0 equiv), CH2Cl2, RT, 4 h; e) 3 (1.3 equiv), TMSOTf, CH2Cl2, ꢀ208C, 49%
over two steps; f) Ac2O, pyridine, RT, overnight, 93%.
though other thioglycoside acti-
vation conditions, for example
using
dimehylthiosulfonium
triflate
could have been explored, we
chose instead to convert 2 into
an alternate glycosyl donor.
Therefore, thioglycoside 2 was
treated with N-bromosuccini-
mide (NBS) in acetone/water (9:1
v/v) to afford hemiacetal 11 in
80% yield. This compound was
subsequently converted to cor-
responding trichloroacetimidate
by treatment with trichloroace-
tonitrile in the presence of cata-
lytic amount of 1,8-diazabicyclo-
[5.4.0]undec-7-ene (DBU). The
freshly made donor was then
used in a reaction with diol ac-
ceptor 3 to give the pentasac-
charide 12 in 49% yield over
two steps. The b stereochemistry
of the newly formed linkage
was established based on the
Scheme 4. Synthesis of PNP ester 1. Reagents and conditions: a) Ethylenediamine, n-butanol, 1008C, 20 h; b) 1:2
v/v CH2Cl2/MeOH, Ac2O, Et3N, 83% over two steps; c) Na, NH3, ꢀ788C, 2 h, 97%; d) cysteamine–HCl (10.0 equiv),
MeOH, UV, 2.5 h, quantitative, e) HOꢀ resin, MeOH, f) concentration, g) N,N-dimethylacetamide, di-p-nitrophenyl
adipate (5.0 equiv), 83%.
1
3JHꢀ1,Hꢀ2 (8.5 Hz) and JCꢀ1,Hꢀ1
(165.5 Hz) values. To confirm the
regioselectivity, a small amount of pentasaccharide 12 was ace-
tylated to generate 12’. Upon comparison of H NMR spectra
verted to free amine by exchange with HOꢀ resin, followed by
coupling with di-p-nitrophenyl adipate[18] in dimethylacetamide
to yield the desired highly reactive p-nitrophenol (PNP) ester
1 in 83% overall yield. Conversion of 1 into the corresponding
human serum albumin (HSA) conjugate was then done by
treatment of HSA with 1 in phosphate buffer (pH 7.5). The
MALDI-MS spectrum of the resulting glycoconjugate showed
two peaks, one centred around m/z=45693 and another at
m/z=91377, corresponding to the +2 and +1 charge states
1
of these two compounds, a broad signal at 4.05 ppm in 12
shifted to 5.46 ppm in 12’ and appeared as a doublet of dou-
blets (J=3.6 and 0.6 Hz). The values of these coupling con-
stants indicated that the acetyl group was introduced onto O-
4’ of the lactose moiety, confirming that the newly introduced
glycosidic linkage was b-(1!3) not b-(1!4).
ꢀ 2013 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ChemistryOpen 2013, 2, 156 – 163 158

www.chemistryopen.org
methylacetamide (0.5 mL) and treated with di-p-nitrophenyl adi-
pate (18 mg, 46.4 mmol). After stirring at RT for 4 h, the solution
was concentrated in vacuo to dryness. The residue was subjected
to C18 chromatography using gradient elution (0.5% aq AcOH!
MeOH/0.5% aq AcOH (60:40 v/v) to give 1 as a white foam after
of the protein, respectively, both bound to 21 pentasaccharide
units.
Conclusions
1
lyophilization (10 mg, 83%): H NMR (600 MHz, CD3OD): d=8.29 (d,
In conclusion, we have achieved the synthesis of LNPFIII func-
tionalized with reactive p-nitrophenol ester (PNP) and the cor-
responding human serum albumin (HSA) conjugate. The syn-
thetic strategy features two highly regio- and stereoselective
glycosylations for the construction of disaccharide 10 and pen-
tasaccharide 12 based on the reactivity difference between
two hydroxyl groups in acceptor 6 and 3, respectively. Birch re-
duction enabled the deprotection of benzyl ethers while leav-
ing the octenyl linker intact, which allowed further functionali-
zation to form PNP ester 1 and, in turn, the HSA conjugate.
Studies on the use of this HSA conjugate in animal models of
graft survival are ongoing.
J=9.2 Hz, 2H, Ar), 7.37 (d, J=9.2 Hz, 2H, Ar), 5.05 (d, J=4.0 Hz,
1H, H-1’’’’), 4.83–4.82 (m, 1H, H-5’’’’), 4.69 (d, J=8.1 Hz, 1H, H-1’’),
4.43 (d, J=7.6 Hz, 1H, one of H-1, H-1’, H-1’’’), 4.36 (d, J=7.7 Hz,
1H, one of H-1, H-1’, H-1’’’), 4.27 (d, J=7.8 Hz, 1H, one of H-1, H-1’,
H-1’’’), 4.04 (d, J=3.0 Hz, 1H), 3.95 (dd, J=6.3, 3.3 Hz, 1H), 3.92–
3.81 (m, 8H), 3.79–3.75 (m, 3H), 3.71–3.49 (m, 12H), 3.46–3.41 (m,
3H), 3.39–3.36 (m, 1H), 3.35 (t, J=7.0 Hz, 2H, SCH2CH2N), 3.22 (dd,
J=9.1, 7.9 Hz, 1H), 2.66 (t, J=7.1 Hz, 2H, OC(O)CH2), 2.62 (t, J=
7.0 Hz, 2H, SCH2CH2N), 2.53 (t, J=7.3 Hz, 2H, SCH2(CH2)6CH2O), 2.25
(t, J=7.0 Hz, 2H, NHC(O)CH2), 1.97 (s, 3H, NHAc), 1.77–1.73 (m, 4H,
NC(O)CH2(CH2)2CH2C(O)O),
1.61–1.55
(m,
4H,
OCH2CH2-
(CH2)4CH2CH2S), 1.39–1.30 (m, 8H, OCH2CH2(CH2)4CH2CH2S),
1.17 ppm (d, J=6.6 Hz, 3H, H-6’’’’); 13C NMR (126 MHz, CD3OD): d=
174.3 (C=O), 173.1 (C=O), 171.2 (C=O), 155.7 (Ar), 145.4 (Ar), 124.7
(2C, Ar), 122.5 (2C, Ar), 103.6, 102.8, 102.5 (C-1, C-1’, C-1’’’), 102.4
(C-1’’), 98.8 (C-1’’’’), 82.4, 79.1, 75.8, 75.3, 75.2, 75.1, 75.02, 74.99,
73.5 (2C), 73.3, 72.3, 71.4, 70.1, 69.8, 69.5 (OCH2(CH2)6CH2S), 68.6
(2C), 68.4, 66.3 (C-5’’’’), 61.4, 61.0, 60.5, 59.8 (C-6, C-6’, C-6’’, C-6’’’),
56.3 (C-2’’), 38.7 (SCH2CH2N), 35.2 (NHC(O)CH2), 33.2 (OC(O)CH2),
31.2 (SCH2CH2N), 30.8 (SCH2(CH2)6CH2O), 29.3 (2C), 29.0, 28.8, 28.4
(5ꢁSCH2(CH2)6CH2O), 25.6, 24.8, 23.8 (SCH2(CH2)6CH2O, 2ꢁ
NC(O)CH2(CH2)2CH2C(O)O), 21.8 (NHAc), 15.2 ppm (C-6’’’’); HRMS
(ESI): m/z [M+Na]+ calcd for C54H87N3NaO30S: 1312.4987, found:
1312.4986.
Experimental Section
General: All reagents were purchased from commercial sources
and were used without further purification unless noted. Dry sol-
vents used in reactions were purified by successive passage
through columns of alumina and copper under an argon atmos-
phere. All reactions were carried out under a positive pressure of
argon unless otherwise stated, monitored by TLC on silica gel 60
F254 (0.25 mm; Silicycle, Quebec, Canada), and the spots were vi-
sualized under UV light (254 nm) and/or stained by charring with
acidified anisaldehyde solution in EtOH. Column chromatography
was performed on silica gel 60 (40–60 mm) or C18 silica gel (35–
p-Tolyl 2,3,4–6-tetra-O-acetyl-b-d-galactopyranosyl-(1!4)-[2,3,4-
tri-O-benzyl-a-l-fucopyranosyl-(1!3)]-6-O-benzyl-2-deoxy-2-
phthalimido-1-thio-b-d-glucopyranoside (2): A mixture of thiogly-
coside 5 (2.74 g, 5.07 mmol), acceptor 10 (1.70 g, 2.03 mmol) and
powdered 4 ꢂ molecular sieves was suspended in toluene (30 mL)
and stirred at RT for 1 h. The solution was cooled to 08C, and N-io-
dosuccinimide (1.10 g, 4.88 mmol) and silver trifluoromethanesulfo-
nate (125 mg, 0.49 mmol) were added. After stirring at 08C for 2 h,
Et3N (1 mL) was added, and the mixture was filtered through
Celite. The filtrate was concentrated, and the resulting residue was
subjected to flash chromatography (2:1 v/v hexane/EtOAc) to
afford trisaccharide 2 as a white foam (1.90 g, 75%): Rf =0.24 (2:1
1
70 mm, Toronto Research Chemicals). H NMR spectra were record-
ed at 500 or 600 MHz, and chemical shifts were referenced to
CHCl3 (7.26 ppm, CDCl3), CD2HOD (3.31 ppm CD3OD), or HOD
(4.79 ppm, D2O). 13C NMR spectra were recorded at 126 MHz and
chemical shifts were referenced to CDCl3 (77.06 ppm, CDCl3),
CD3OD (49.0 ppm, CD3OD) or external acetone (31.07 ppm, D2O).
Assignments of NMR spectra were made on the basis of 2D experi-
ments (1H–1H COSY, HSQC and HMBC), and the stereochemistry of
the newly formed glycosidic linkages was confirmed by measuring
1
1JCꢀ1,Hꢀ1 values using an H-coupled HSQC experiment. In the data
1
provided below, the resonances on particular residues are indicat-
ed by an increasing number of primes (’) moving from the reduc-
ing to nonreducing end. For example, in 15 H-1 is H-1 of the Glc
residue, H-1’’ is H-1 of the GlcNAc residue, and H-1’’’’ is H-1 of the
Fuc residue. Electrospray ionization mass spectra were recorded on
an Agilent Technologies 6220 TOF spectrometer on samples dis-
solved in CH2Cl2 or MeOH. MALDI mass spectra were obtained in
the linear positive mode of ionization on a Bruker Daltonics
(Bremen, GmbH) UltrafleXtreme MALDI TOF/TOF mass spectrome-
ter using sinapinic acid as the matrix. Optical rotations were mea-
sured on PerkinElmer 241 polarimeter at 22ꢁ28C in units of
degree mL/(gdm).
v/v hexane/EtOAc); [a]D = +7.1 (c=0.9, CHCl3); H NMR (500 MHz,
CDCl3): d=7.75–7.70 (m, 4H, Ar), 7.45–7.01 (m, 24H, Ar), 5.44 (d,
J=10.5 Hz, 1H, H-1), 5.26 (dd, J=3.5, 1.0 Hz, 1H, H-4’), 5.04 (dd,
J=10.4, 8.2 Hz, 1H, H-2’), 4.84–4.79 (m, 4H, H-1’’, H-3’, 2ꢁOCH2Ph),
4.77–4.72 (m, 2H, H-1’, H-3), 4.65–4.60 (m, 3H, H-5’’, 2ꢁOCH2Ph),
4.58 (A of ABq, J=11.7 Hz, 1H, OCH2Ph), 4.53–4.48 (m, 2H, H-2,
OCH2Ph), 4.46, 4.28 (ABq, J=12.3 Hz, 2H, 2ꢁOCH2Ph), 4.18–4.13
(m, 2H, H-4, H-6a’), 3.98 (dd, J=10.7, 5.7 Hz, 1H, H-6b’), 3.92–3.88
(m, 2H, H-3’’, H-6a), 3.85–3.80 (m, 2H, H-2’’, H-6b) 3.64 (d, J=
1.3 Hz, 1H, H-4’’), 3.57–3.55 (m, 2H, H-5, H-5’), 2.29 (s, 3H, ArMe),
2.03 (s, 3H, OAc), 2.02 (s, 3H, OAc), 1.97 (s, 3H, OAc), 1.86 (s, 3H,
OAc), 1.21 ppm (d, J=6.5 Hz, 3H, H-6’’); 13C NMR (126 MHz, CDCl3):
d 170.0 (C=O), 169.8 (C=O), 168.7 (C=O), 138.9 (Ar), 138.7 (Ar),
138.2 (Ar), 138.1 (Ar), 137.9 (Ar), 134.2 (Ar), 133.3 (Ar), 131.8 (Ar),
129.6 (Ar), 128.6 (Ar), 128.3 (Ar), 128.24 (Ar), 128.17 (Ar), 128.1 (Ar),
128.02 (Ar), 127.97 (Ar), 127.86 (Ar), 127.4 (Ar), 127.2 (Ar), 127.1 (Ar),
127.0 (Ar), 123.7 (Ar), 99.5 (C-1’), 97.6 (C-1’’), 84.4 (C-1), 79.8 (C-3’’),
79.6 (C-5), 77.2 (C-4’’), 75.0 (C-4), 74.5 (C-2’’) 74.2 (OCH2Ph), 73.64
(C-3), 73.58, 73.0, 72.3 (3ꢁOCH2Ph), 71.0 (C-3’), 70.4 (C-5’), 69.0 (C-
2’), 67.85 (C-6), 66.76 (C-4’), 66.5 (C-5’’), 60.2 (C-6’), 55.6 (C-2), 21.1,
20.7, 20.62, 20.55, 20.54 ppm (4ꢁOAc, ArMe); 16.7 (C-6’’); HRMS
6-[[2-[[8-(b-d-galactopyranosyl-(1!4)-[a-l-fucopyranosyl-(1!3)]-
2-acetamido-2-deoxy-b-d-glucopyranosyl-(1!3)-b-d-galactopyr-
anosyl-(1!4)-b-d-glucopyranosyl-oxy)octyl]thiol]ethyl]amino]-6-
oxo-hexanoic acid p-nitrophenyl ester (1): Compound 15 (10 mg,
9.3 mmol) was dissolved in MeOH (5 mL) and treated with Amber-
lite IR400 HOꢀ ion-exchange resin to convert the hydrochloride salt
to the free amine. The solution was filtered, concentrated and
dried overnight in vacuo. The residue was dissolved in N,N-di-
ꢀ 2013 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ChemistryOpen 2013, 2, 156 – 163 159

www.chemistryopen.org
(ESI): m/z [M+Na]+ calcd for C69H73NNaO19S: 1274.4390, found:
1274.4385.
2H, Ar), 5.56 (d, J=10.3 Hz, 1H, H-1), 4.63, 4.58 (ABq, J=11.4 Hz,
2H, 2ꢁOCH2Ph), 4.35 (dd, J=10.3, 8.3 Hz, 1H, H-3), 4.21 (app t, J=
10.3 Hz, 1H, H-2), 3.85 (dd, J=10.5, 4.5 Hz, 1H, H-6a), 3.81 (dd, J=
10.5, 4.5 Hz, 1H, H-6b), 3.68–3.60 (m, 2H, H-4, H-5), 2.30 ppm (s,
3H, OAc); 13C NMR (126 MHz; CDCl3): d=138.2 (Ar), 137.7 (Ar),
134.2 (Ar), 133.3 (Ar), 131.7 (Ar), 129.6 (Ar), 128.5 (Ar), 128.2 (Ar),
127.9 (Ar), 127.8 (Ar), 83.8 (C-1), 77.8 (C-5), 73.8 (OCH2Ph), 73.6 (C-
4), 72.8 (C-3), 70.5 (C-6), 55.4 (C-2), 21.1 ppm (ArMe); HRMS (ESI):
m/z [M+Na]+ calcd for C28H27NNaO6S: 528.1451, found: 528.1451.
7-Octen-1-yl 2,6-di-O-benzyl-b-d-galactopyranosyl-(1!4)-2,3,6-
tri-O-benzyl-b-d-glucopyranoside (3): NaOMe (1.0m, 2.7 mL) was
added to a solution of 7 (2.89 g, 3.87 mmol) in CH2Cl2/MeOH (1:3
v/v, 40 mL). After stirring at RT overnight, the solution was neutral-
ized with Amberlite IR120 H+ ion-exchange resin. The solution was
filtered and the filtrate was concentrated to afford 8 as a white
solid (1.61 g, 92%). A portion of 8 (1.65 g, 3.65 mmol) and p-TsOH
(41 mg) were suspended in a mixture of dry N,N-dimethylform-
amide (DMF; 8 mL) and 2,2-dimethoxypropane (24 mL). After stir-
ring at 858C for 1.5 h, the solution was cooled to RT, neutralized
with Et3N (1 mL), concentrated in vacuo and dried. The resulting
residue and BnBr (2.9 mL, 24.3 mmol) were dissolved in dry DMF
(40 mL), to which NaH (60%, 1.22 g, 30.5 mmol) was added in por-
tions at 08C, followed by vigorous stirring. After stirring overnight
at RT, MeOH (4 mL) was added. The solution was concentrated in
vacuo, dissolved in EtOAc (200 mL) and washed with H2O and
brine. The organic layer was dried over Na2SO4, filtered and con-
centrated to dryness. Subsequently, the obtained crude residue
was treated with 80% aq HOAc (160 mL) at 808C for 3 h. The solu-
tion was concentrated, dissolved in EtOAc (200 mL) and washed
with saturated aq NaHCO3, H2O and brine. The organic layer was
dried over Na2SO4, filtered, concentrated and the residue subjected
to flash chromatography (5:2 v/v hexane/EtOAc) to afford diol 3 as
a white solid (2.07 g, 63% over three steps): Rf =0.40 (2:1 v/v
hexane/EtOAc); [a]D = +16.4 (c=0.9, CHCl3); 1H NMR (500 MHz,
CDCl3): d=7.39–7.22 (m, 25H, Ar), 5.81 (ddt, J=17.0, 10.3, 6.7 Hz,
1H, CH=CH2), 5.02–4.92 (m, 3H, CH=CH2, OCH2Ph), 4.91, 4.72 (ABq,
J=11.0 Hz, 2H, 2ꢁOCH2Ph), 4.82, 4.68 (ABq, J=11.5 Hz, 2H, 2ꢁ
OCH2Ph), 4.79 (A of ABq, J=11.0 Hz, 1H, OCH2Ph), 4.61 (A of ABq,
J=12.5 Hz, 1H, OCH2Ph), 4.47–4.44 (m, 3H, H-1’, 2ꢁOCH2Ph), 4.41–
4.38 (m, 2H, H-1, OCH2Ph), 3.99 (app t, J=9.5 Hz, 1H, H-4), 3.97–
3.92 (m, 2H, H-4’, octenyl OCH2), 3.82 (dd, J=11.0, 4.0 Hz, 1H, H-
6a), 3.77 (dd, J=11.0, 2.0 Hz, 1H, H-6b), 3.64–3.58 (m, 2H, H-3, H-
6a’), 3.54–3.49 (m, 2H, H-6b’, octenyl OCH2), 3.45–3.39 (m, 4H, H-2,
H-2’, H-3’, H-5), 3.37–3.35 (m, 1H, H-5’), 2.48 (d, J=3.5 Hz, 1H, 4’-
OH), 2.41 (d, J=4.0 Hz, 1H, 3’-OH), 2.06–2.02 (m, 2H, OCH2CH2-
(CH2)3CH2CH=CH2), 1.69–1.62 (m, 2H, OCH2CH2(CH2)3CH2CH=CH2),
1.45–1.31 ppm (m, 6H, OCH2CH2(CH2)3CH2CH=CH2); 13C NMR
(126 MHz, CDCl3): d=139.2 (Ar), 139.1 (CH=CH2), 138.7 (Ar), 138.4
(Ar), 138.3 (Ar), 138.0 (Ar), 128.5 (Ar), 128.4 (Ar), 128.32 (Ar), 128.30
(Ar), 128.08 (Ar), 128.06 (Ar), 128.0 (Ar), 127.93 (Ar), 127.86 (Ar),
127.7 (Ar), 127.6 (Ar), 127.57 (Ar), 127.54 (Ar), 127.3 (Ar), 114.3 (CH=
CH2), 103.7 (C-1), 102.6 (C-1’), 82.9 (C-3), 81.8, 80.1 (C-2, C-2’), 76.7
(C-4), 75.2 (OCH2Ph), 75.1 (C-5), 74.93, 74.90 (2ꢁOCH2Ph), 73.6 (C-
3’), 73.5, 73.2 (2ꢁOCH2Ph), 72.9 (C-5’), 70.0 (octenyl OCH2), 68.8 (C-
4’), 68.7 (C-6’), 68.4 (C-6), 33.8, 29.7, 29.0, 28.9, 26.1 ppm (5ꢁocten-
yl CH2); HRMS (ESI): m/z [M+Na]+ calcd for C55H66NaO11: 925.4497,
found: 925.4489.
7-Octen-1-yl 2,3,4,6-tetra-O-acetyl-b-d-galactopyranosyl-(1!4)-
2,3,6-tri-O-acetyl-b-d-glucopyranoside (7): d-Lactose (10.00 g,
29.2 mmol) and NaOAc (2.5 g, 30.5 mmol) were heated in Ac2O
(80 mL) at 1008C for 5 h. The solution was allowed to cool to RT
and poured into ice water (1 L). The precipitate was filtered and re-
crystallized from EtOAc/hexane to yield peracetylated lactose as
colourless crystals (15.60 g, 79%). A portion of this compound
(6.78 g, 10 mmol), 7-octen-1-ol (2.4 mL, 16 mmol) and 4 ꢂ molecu-
lar sieves was dissolved in CH2Cl2 (80 mL) and stirred at RT for
0.5 h. The solution was cooled to 08C, and BF3·Et2O (3.8 mL,
30 mmol) was added. After stirring at RT for 24 h, Et3N (5 mL) was
added, and the reaction mixture was filtered through Celite. The
filtrate was concentrated and the residue was subjected to flash
chromatography (4:3 v/v hexane/EtOAc) to afford 7 as white foam
(3.2 g, 43%): Rf =0.39 (1:1 v/v hexane/EtOAc); [a]D =ꢀ11.6 (c=1.1,
CHCl3); 1H NMR (500 MHz, CDCl3): d=5.79 (ddt, J=17.0, 10.3,
6.7 Hz, 1H, CH=CH2), 5.34 (dd, J=3.4, 1.1 Hz, 1H, H-4’), 5.19 (app t,
J=9.5 Hz, 1H, H-3), 5.10 (dd, J=10.4, 7.9 Hz, 1H, H-2’), 5.01–4.91
(m, 3H, CH=CH2, H-3’), 4.88 (dd, J=9.5, 8.0 Hz, 1H, H-2), 4.49–4.46
(m, 2H, H-1’, H-6a), 4.45 (d, J=8.0 Hz, 1H, H-1), 4.15–4.06 (m, 3H,
H-6b, H-6a’, H-6b’), 3.88–3.85 (m, 1H, H-5’), 3.82 (dt, J=9.7, 6.8 Hz,
1H, octenyl OCH2), 3.79 (app t, J=9.5 Hz, 1H, H-4), 3.59 (ddd, J=
9.9, 5.1, 2.1 Hz, 1H, H-5), 3.44 (dt, J=9.7, 6.8 Hz, 1H, octenyl OCH2),
2.15 (s, 3H, OAc), 2.11 (s, 3H, OAc), 2.06–2.03 (m, 14H, 4ꢁOAc,
OCH2CH2(CH2)3CH2CH=CH2), 1.96 (s, 3H, OAc), 1.57–1.51 (m, 2H,
OCH2CH2(CH2)3CH2CH=CH2), 1.39–1.25 ppm (m, 6H, OCH2CH2-
(CH2)3CH2CH=CH2); 13C NMR (126 MHz, CDCl3): d=170.4 (C=O),
170.3 (C=O), 170.1 (C=O), 170.0 (C=O), 169.8 (C=O), 169.6 (C=O),
169.1 (C=O), 139.0 (CH=CH2), 114.3 (CH=CH2), 101.1 (C-1’), 100.6 (C-
1), 76.4 (C-4), 72.9 (C-3), 72.6 (C-5), 71.8 (C-2), 71.0 (C-3’), 70.7 (C-5’),
70.2 (octenyl OCH2), 69.1 (C-2’), 66.6 (C-4’), 62.1 (C-6), 60.8 (C-6’),
33.7, 29.4, 28.84, 28.77, 25.7 (5ꢁoctenyl CH2); 20.9, 20.8, 20.71,
20.66, 20.65 (2C), 20.5 ppm (7ꢁOAc); HRMS (ESI): m/z [M+Na]+
calcd for C34H50NaO18: 769.2889, found: 769.2880.
p-Tolyl 2,3,4–6-tetra-O-acetyl-b-d-galactopyranosyl-(1!4)-6-O-
benzyl-2-deoxy-2-phthalimido-1-thiol-b-d-glucopyranoside (10):
A mixture of trichloroacetimidate 4 (1.80 g, 3.65 mmol), diol 6
(1.76 g 3.48 mmol) and powdered 4 ꢂ molecular sieves was sus-
pended in CH2Cl2 (40 mL) and stirred at RT for 1 h. The solution
was cooled to ꢀ408C, and trimethylsilyl trifluoromethanesulfonate
(TMSOTf; 63 mL) was added drop wise. After stirring at ꢀ408C for
2 h, the mixture was allowed to warm to RT. Et3N (1 mL) was
added and the mixture was filtered through Celite. The filtrate was
concentrated and subjected to flash chromatography (4:3 v/v
hexane/EtOAc) to afford 10 as a white foam (2.21 g, 70%): Rf =0.39
(1:1 v/v hexane/EtOAc); [a]D = +18.5 (c=0.9, CHCl3); 1H NMR
(500 MHz, CDCl3): d=7.88–7.82 (m, 2H, Ar), 7.75–7.71 (m, 2H, Ar),
7.41–7.37 (m, 2H, Ar), 7.36–7.30 (m, 5H, Ar), 7.02–6.99 (m, 2H, Ar),
5.53 (d, J=10.5 Hz, 1H, H-1), 5.31 (dd, J=3.5, 1.0 Hz, 1H, H-4’), 5.18
(dd, J=10.5, 8.0 Hz, 1H, H-2’), 4.93 (dd, J=10.5, 3.5 Hz, 1H, H-3’),
4.68, 4.52 (ABq, J=12.0 Hz, 2H, 2ꢁOCH2Ph), 4.50 (d, J=8.0 Hz, 1H,
H-1’), 4.39 (dd, J=10.5, 8.0 Hz, 1H, H-3), 4.20 (app t, J=10.5 Hz,
1H, H-2), 4.05–4.00 (m, 3H, H-6a’, H-6b’, 3-OH), 3.89 (dt, J=6.5,
p-Tolyl
6-O-benzyl-2-deoxy-2-phthalimido-1-thio-b-d-glucopy-
(1.82 g, 3.62 mmol) and
ranoside (6): Benzylidene acetal
9
BH3·NMe3 (1.06 g, 14.50 mmol) were dissolved in THF (26 mL) and
cooled to 08C, then an ice-cold solution of AlCl3 (2.90 g,
21.74 mmol) in THF (10 mL) was added. After stirring at RT for 3 h,
the solution was concentrated, dissolved in EtOAc (200 mL) and
washed with saturated aq NaHCO3, H2O and brine. The organic
layer was dried over Na2SO4, filtered, concentrated and subjected
to flash chromatography (hexane/EtOAc 3:4 v/v) to afford diol 6 as
a white solid (1.50 g, 82%): Rf =0.29 (3:4 v/v hexane/EtOAc); [a]D =
1
+16.3 (c=1.0, CHCl3); H NMR (500 MHz; CDCl3): d=7.87–7.85 (m,
2H, Ar), 7.75–7.74 (m, 2H, Ar), 7.40–7.29 (m, 7H, Ar), 7.04–7.02 (m,
ꢀ 2013 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ChemistryOpen 2013, 2, 156 – 163 160

www.chemistryopen.org
1.0 Hz, 1H, H-5’), 3.76–3.64 (m, 4H, H-4, H-5, H-6a, H-6b), 2.27 (s,
3H, ArMe), 2.11 (s, 3H, OAc), 2.00 (s, 3H, OAc), 1.97 (s, 3H, OAc),
1.89 ppm (s, 3H, OAc); 13C NMR (126 MHz, CDCl3): d=170.4 (C=O),
170.1 (C=O), 169.9 (C=O), 169.2 (C=O), 168.2 (C=O), 167.5 (C=O),
138.3 (Ar), 138.2 (Ar), 134.1 (Ar), 133.7 (Ar), 131.9 (Ar), 131.8 (Ar),
129.6 (Ar), 128.5 (Ar), 127.84 (Ar), 127.81 (Ar), 123.6 (Ar), 123.3 (Ar),
101.6 (C-1’), 83.4 (C-1), 81.8 (C-4), 78.2 (C-5), 73.7 (OCH2Ph), 71.2 (C-
5’), 70.87 (C-3), 70.78 (C-3’), 68.7 (C-2’), 68.2 (C-6), 66.8 (C-4’), 61.4
(C-6’), 55.2 (C-2), 21.1, 20.7, 20.6, 20.5, 20.3 ppm (5C, 4ꢁOAc,
ArMe); HRMS (ESI): m/z [M+Na]+ calcd for C42H45NNaO15S:
858.2402, found: 858.2395.
(Ar), 127.83 (Ar), 127.75 (Ar), 127.5 (Ar), 127.4 (Ar), 127.2 (2C, Ar),
127.1 (Ar), 127.0 (Ar), 126.6 (Ar), 126.3 (Ar), 123.3 (Ar), 114.2 (CH=
CH2), 103.5 (C-1), 102.0 (C-1’), 99.6 (C-1’’’), 99.0 (C-1’’), 97.6 (C-1’’’’),
83.5 (C-3), 82.9 (C-2’), 81.8 (C-2), 79.7 (C-3’’’’), 78.1 (C-3’), 77.2 (C-
4’’’’), 75.9 (C-4), 75.4 (OCH2Ph), 75.3 (C-4’’), 75.1 (C-5’’), 74.9
(OCH2Ph), 74.75, 74.72 (C-2’’’’, C-5), 74.21, 74.16, 73.8, 73.4, 73.0,
72.9 (6ꢁOCH2Ph), 72.64, 72.60 (C-3’’, C-5’), 72.4 (OCH2Ph), 71.0 (C-
3’’’), 70.5 (C-5’’’), 69.9 (octenyl OCH2), 69.1 (C-2’’’), 68.5, 68.0, 67.9
(C-6, C-6’, C-6’’), 67.5 (C-4’), 66.8 (C-4’’’), 66.6 (C-5’’’’), 60.3 (C-6’’’),
56.2 (C-2’’), 33.7, 29.7, 28.9, 28.8, 26.0 (5ꢁoctenyl CH2), 20.7, 20.62,
20.56, 20.5 (4ꢁOAc), 16.8 ppm (C-6’’’’); HRMS (ESI): m/z [M+Na]+
calcd for C117H131NNaO30: 2052.8648, found: 2052.8612.
7-Octen-1-yl 2,3,4–6-tetra-O-acetyl-b-d-galactopyranosyl-(1!4)-
[2,3,4-tri-O-benzyl-a-l-fucopyranosyl-(1!3)]-6-O-benzyl-2-
deoxy-2-phthalimido-b-d-glucopyranosyl-(1!3)-2,6-di-O-benzyl-
b-d-galactopyranosyl-(1!4)-2,3,6-tri-O-benzyl-b-d-glucopyrano-
side (12): N-Bromosuccinimide (NBS; 287 mg, 1.62 mmol) was
added to a solution of trisaccharide 2 (809 mg, 0.65 mmol) in ace-
tone/H2O (9:1 v/v, 7 mL) at 08C. After stirring at 08C for 0.5 h, satu-
rated aq NaHCO3 (2 mL) was added. The solution was concentrat-
ed, and the residue was dissolved in EtOAc (80 mL) and washed
with H2O and brine. The organic layer was dried over Na2SO4, fil-
tered, concentrated and subjected to flash chromatography (4:5
v/v hexane/EtOAc) to afford 11 as a white solid (590 mg, 80%). A
solution of 11 (455 mg, 0.39 mmol) in CH2Cl2 (4 mL) was treated
with trichloroacetonitrile (0.28 mL, 2.75 mmol) and catalytic
amount of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), and stirred at
RT for 4 h. Concentration and flash chromatography (1:1 v/v hex-
anes/EtOAc) afforded the trichloroacetimidate that was immediate-
ly used in the next step. The trichloroacetimidate (387 mg,
0.3 mmol), diol 3 (354 mg, 0.39 mmol) and powdered 4 ꢂ molecu-
lar sieves were suspended in CH2Cl2 (4 mL) and stirred at RT for
1 h. The solution was then cooled to ꢀ308C, to which TMSOTf
(14 mL) was added. The mixture was allowed to warm to RT, and
after stirring at ꢀ308C for 2 h, Et3N (1 mL) was added, and the mix-
ture was filtered through Celite. The filtrate was concentrated and
subjected to flash chromatography (5:2 v/v hexane/EtOAc) to
afford 12 as a white foam (390 mg, 49% over two steps): Rf =0.46
(5:3 v/v hexane/EtOAc); [a]D = +5.5 (c=1.0, CHCl3); 1H NMR
(600 MHz, CDCl3): d=7.42–7.07 (m, 45H, Ar), 7.01 (d, J=7.2 Hz, 2H,
Ar), 6.79 (d, J=7.2 Hz, 2H, Ar), 5.78 (ddt, J=17.0, 10.3, 6.7 Hz, 1H,
CH=CH2), 5.32 (d, J=8.5 Hz, 1H, H-1’’), 5.25 (dd, J=3.5, 0.8 Hz, 1H,
H-4’’’), 5.03 (dd, J=10.4, 8.2 Hz, 1H, H-2’’’), 4.97 (dq, J=17.1,
1.8 Hz, 1H, CH=CH2), 4.93–4.89 (m, 2H, CH=CH2, OCH2Ph), 4.84–
4.78 (m, 4H, H-1’’’’, H-3’’’, 2 ꢁ OCH2Ph), 4.74–4.65 (m, 5H, H-1’’’, H-
3’’, 3ꢁOCH2Ph), 4.60–4.53 (m, 4H, H-5’’’’, 3ꢁOCH2Ph), 4.48–4.42 (m,
4H, H-2’’, 3ꢁOCH2Ph), 4.33 (A of ABq, J=12.2 Hz, 2H, 2ꢁOCH2Ph),
4.30–4.25 (m, 2H, H-1’, OCH2Ph), 4.21–4.17 (m, 3H, H-1, 2ꢁ
OCH2Ph), 4.16–4.12 (m, 3H, H-4’’, H-6a’’’, OCH2Ph), 4.05 (br s, 1H, H-
4’), 3.95 (dd, J=10.9, 5.9 Hz, 1H, H-6b’’’), 3.85–3.81 (m, 4H, H-3’’’’,
H-4, H-6a’’, octenyl OCH2), 3.75 (dd, J=12.2 Hz, 1H, H-2’’’’), 3.71–
3.68 (m, 2H, H-6b’’, H-6a’), 3.61–3.58 (m, 3H, H-4’’’’, H-5’’, H-5’’’),
3.49 (dd, J=9.6, 5.6 Hz, 1H, H-6b’), 3.42 (dd, J=10.8 Hz, 4.2 Hz, 1H,
H-6a), 3.42–3.35 (m, 5H, H-2’, H-3’, H-3, H-5’, octenyl OCH2), 3.32–
3.27 (m, 2H, H-2, H-6b), 2.96 (ddd, J=9.6, 4.2, 1.8 Hz, 1H, H-5), 2.71
(br s, 1H, 4’-OH), 2.03–1.99 (m, 8H, 2ꢁOAc, OCH2CH2(CH2)3CH2CH=
CH2), 1.96 (s, 3H, OAc), 1.85 (s, 3H, OAc), 1.62–1.55 (m, 2H,
7-Octen-1-yl 2,3,4–6-tetra-O-acetyl-b-d-galactopyranosyl-(1!4)-
[2,3,4-tri-O-benzyl-a-l-fucopyranosyl-(1!3)]-6-O-benzyl-2-
deoxy-2-phthalimido-b-d-glucopyranosyl-(1!3)-4-O-acetyl-2,6-
di-O-benzyl-b-d-galactopyranosyl-(1!4)-2,3,6-tri-O-benzyl-b-d-
glucopyranoside (12’): A solution of 12 (10 mg, 4.9 mmol) in pyri-
dine (1 mL) and Ac2O (0.5 mL, 5.3 mmol) was stirred overnight at
RT, concentrated in vacuo, and the residue subjected to flash chro-
matography (5:2 v/v hexane/EtOAc) to afford 12’ as a white foam
(9.5 mg, 93%): Rf =0.45 (5:3 v/v hexane/EtOAc); [a]D = +4.2 (c=
0.8, CHCl3); 1H NMR (600 MHz, CDCl3): d=7.45–7.09 (m, 45H, Ar),
7.02–7.01 (m, 2H, Ar), 6.87–6.85 (m, 2H, Ar), 5.80 (ddt, J=17.0,
10.3, 6.7 Hz, 1H, CH=CH2), 5.46 (dd, J=3.6, 0.6 Hz, 1H, H-4’), 5.28
(dd, J=3.6, 1.0 Hz, 1H, H-4’’’), 5.26 (d, J=8.2 Hz, 1H, H-1’’), 5.04
(dd, J=10.4, 8.2 Hz, 1H, H-2’’’), 5.00–4.97 (m, 1H, CH=CH2), 4.95–
4.92 (m, 2H, CH=CH2, OCH2Ph), 4.90 (A of ABq, J=10.5 Hz, 1H,
OCH2Ph), 4.86–4.83 (m, 3H, H-1’’’, H-3’’’, OCH2Ph), 4.81, 4.57 (ABq,
J=11.8 Hz, 2H, 2ꢁOCH2Ph), 4.78 (d, J=3.6 Hz, 1H, H-1’’’’), 4.75 (dd,
J=10.2, 9.0 Hz, 1H, H-3’’), 4.69–4.63 (m, 5H, H-5’’’’, 4ꢁOCH2Ph),
4.55 (A of ABq, J=11.7 Hz, 1H, OCH2Ph), 4.47 (A of ABq, J=
12.2 Hz, 1H, OCH2Ph), 4.43–4.40 (m, 3H, H-2’’, 2 ꢁ OCH2Ph), 4.30–
4.26 (m, 3H, H-1’, 2 ꢁ OCH2Ph), 4.23–4.15 (m, 5H, H-1, H-4’’, H-6a’’’,
2ꢁOCH2Ph), 4.00 (A of ABq, J=11.8 Hz, 1H, OCH2Ph), 3.97 (dd, J=
10.8, 5.7 Hz, 1H, H-6b’’’), 3.93 (dd, J=5.4, 3.0 Hz, 1H, H-6a’’), 3.89–
3.83 (m, 4H, H-3’’’’, H-4, H-6b’’, octenyl OCH2), 3.77 (dd, J=10.2,
3.7 Hz, 1H, H-2’’’’), 3.63–3.60 (m, 2H, H-4’’’’, H-5’’’), 3.56–3.52 (m,
2H, H-3’, H-5’’), 3.47–3.41 (m, 3H, H-5’, H-6a, octenyl OCH2), 3.38
(m, 2H, H-3, H-6a’), 3.33–3.29 (m, 4H, H-2, H-2’, H-6b, H-6b’), 2.98–
2.96 (ddd, J=9.6, 3.6, 1.8 Hz, 1H, H-5), 2.09 (s, 3H, OAc), 2.05 (s,
3H, OAc), 2.03–2.02 (m, 5H, OAc, OCH2CH2(CH2)3CH2CH=CH2), 1.97
(s, 3H, OAc), 1.85 (s, 3H, OAc), 1.63–1.59 (m, 2H, OCH2CH2-
(CH2)3CH2CH=CH2), 1.39–1.29 (m, 6H, OCH2CH2(CH2)3CH2CH=CH2),
1.21 ppm (d, J=6.0 Hz, 3H, C-6’’’’); 13C NMR (126 MHz; CDCl3): d=
170.02 (C=O), 170.01 (C=O), 169.96 (C=O), 169.86 (C=O), 168.8 (C=
O), 139.12 (Ar), 139.05 (CH=CH2), 138.89 (Ar), 138.69 (Ar), 138.68
(Ar), 138.4 (Ar), 138.28 (Ar), 138.27 (Ar), 138.23 (Ar), 138.19 (Ar),
133.8 (Ar), 131.3 (Ar), 128.5 (Ar), 128.31 (Ar), 128.26 (Ar), 128.15 (Ar),
128.13 (Ar), 128.09 (Ar), 128.01 (Ar), 127.94 (Ar), 127.92 (Ar), 127.90
(Ar), 127.83 (Ar), 127.79 (2C, Ar), 127.78 (Ar), 127.53 (Ar), 127.48
(Ar), 127.41 (Ar), 127.3 (Ar), 127.13 (Ar), 127.11 (Ar), 127.00 (Ar),
126.9 (Ar), 126.4 (Ar), 123.3 (Ar), 114.2 (CH=CH2), 103.6 (C-1), 102.0
(C-1’), 99.5 (C-1’’’), 99.1 (C-1’’), 97.2 (C-1’’’’), 82.6 (C-3), 81.6, 78.84,
78.79 (C-2, C-2’, C-3’), 79.7 (C-3’’’’), 77.2 (C-4’’’’), 75.7 (C-4), 75.4 (C-
5’’), 75.2 (OCH2Ph), 74.96 (C-4’’), 74.92 (OCH2Ph), 74.7, 74.5 (C-5, C-
2’’’’), 74.20, 74.15, 73.6, 73.50, 73.0, 72.7 (6ꢁOCH2Ph), 72.6 (C-5’),
72.4 (OCH2Ph), 72.0 (C-3’’), 71.0 (C-3’’’), 70.4 (C-5’’’), 69.94 (C-4’),
69.90 (octenyl OCH2), 69.0 (C-2’’’), 68.3, 67.7, 67.6 (C-6, C-6’, C-6’’),
66.8 (C-4’’’), 66.4 (C-5’’’’), 60.2 (C-6’’’), 56.6 (C-2’’), 33.7, 29.7, 28.9,
28.8, 26.0 (5ꢁoctenyl CH2), 20.83, 20.75, 20.64, 20.56, 20.54 (5ꢁ
OAc), 16.7 ppm (C-6’’’’); HRMS (ESI): m/z [M+Na]+ calcd for
C119H133NNaO31: 2094.8754, found: 2094.8751.
OCH2CH2(CH2)3CH2CH=CH2),
1.37–1.26
(m,
6H,
OCH2CH2-
(CH2)3CH2CH=CH2), 1.19 ppm (d, J=6.6 Hz, 3H, H-6’’’’); 13C NMR
(126 MHz, CDCl3): d=170.1 (C=O), 170.0 (C=O), 169.9 (C=O), 168.7
(C=O), 139.10 (Ar), 139.06 (CH=CH2), 138.8 (Ar), 138.75 (Ar), 138.65
(Ar), 138.57 (Ar), 138.56 (Ar), 138.4 (Ar), 138.2 (Ar), 137.6 (Ar), 133.9
(Ar), 131.3 (Ar), 128.7 (Ar), 128.4 (Ar), 128.27 (Ar), 128.25 (2C, Ar),
128.16 (Ar), 128.13 (Ar), 128.11 (Ar), 128.02 (Ar), 128.0 (Ar), 127.85
ꢀ 2013 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ChemistryOpen 2013, 2, 156 – 163 161

www.chemistryopen.org
7-Octen-1-yl b-d-galactopyranosyl-(1!4)-[2,3,4-tri-O-benzyl-a-l-
fucopyranosyl-(1!3)]-6-O-benzyl-2-deoxy-2-acetamido-b-d-glu-
copyranosyl-(1!3)-2,6-di-O-benzyl-b-d-galactopyranosyl-(1!4)-
2,3,6-tri-O-benzyl-b-d-glucopyranoside (13): A solution of penta-
saccharide 12 (352 mg, 0.17 mmol) in n-butanol (15 mL) was treat-
ed with ethylenediamine (3 mL, 44.9 mmol), followed by stirring at
1008C for 20 h. The solution was concentrated in vacuo to dryness.
The crude residue was dissolved in CH2Cl2/MeOH (1:2 v/v, 6 mL), to
which Ac2O (1 mL) and Et3N (1 mL) were added. After stirring at RT
for 5 h, the solution was concentrated, and the residue subjected
to flash chromatography (3:2 v/v toluene/acetone). Further purifi-
cation by C18 chromatography (1:1 v/v MeOH/H2O!MeOH) afford-
ed 13 as a white foam (255 mg, 83%). Rf =0.51 (4:5 v/v toluene/
acetone); [a]D =ꢀ19.6 (c=1.0, CHCl3); 1H NMR (600 MHz, CDCl3):
d=7.42–7.19 (m, 45H), 5.80 (ddt, J=17.0, 10.3, 6.7 Hz, 1H, CH=
CH2), 5.67 (d, J=7.2H, 1H, NH), 5.16 (d, J=7.5 Hz, 1H, H-1’’), 5.05
(d, J=3.6 Hz, 1H, H-1’’’’), 5.00–4.97 (m, 2H, CH=CH2, OCH2Ph),
4.94–4.87 (m, 4H, CH=CH2, 3ꢁOCH2Ph), 4.74–4.70 (m, 4H, 4ꢁ
OCH2Ph), 4.66–4.63 (m, 2H, 2ꢁOCH2Ph), 4.60–4.55 (m, 3H, 3ꢁ
OCH2Ph), 4.53, 4.47 (ABq, J=12.2 Hz, 2H, 2ꢁOCH2Ph), 4.44–4.38
(m, 4H, H-1’, H-1’’’, 2ꢁOCH2Ph), 4.35–4.32 (m, 2H, H-1, H-3’’), 4.29
(A of ABq, J=12.0 Hz, 1H, OCH2Ph), 4.12–4.08 (m, 2H, H-5’’’’, OH),
4.05–4.01 (m, 3H, H-2’’’’), 3.94–3.86 (m, 5H, H-3’’’’, H-6a’’’, octenyl
OCH2), 3.78–3.76 (m, 1H, H-4’’), 3.74–3.65 (m, 6H, H-6b’’’), 3.62–
3.58 (m, 2H, H-4’’’’), 3.54–3.46 (m, 7H, H-2’, H-2’’’, H-3, H-3’, octenyl
OCH2), 3.44–3.33 (m, 4H, H-2, H-2’’), 3.30–3.27 (m, 1H), 2.99–2.97
(m, 2H, OH), 2.72 (br s, 1H, OH), 2.05–2.01 (m, 2H, OCH2CH2-
(CH2)3CH2CH=CH2), 1.64–1.62 (m, 2H, OCH2CH2(CH2)3CH2CH=CH2),
1.40–1.32 (m, 9H, NHAc, OCH2CH2(CH2)3CH2CH=CH2), 1.11 ppm (d,
J=6.0 Hz, 3H, H-6’’’’); 13C NMR (126 MHz, CDCl3): d=170.9 (C=O),
139.2 (Ar), 139.1 (CH=CH2), 139.0 (Ar), 138.7 (Ar), 138.44 (Ar), 138.43
(Ar), 138.38 (Ar), 138.2 (Ar), 137.5 (Ar), 128.6 (Ar), 128.51 (Ar), 128.47
(Ar), 128.31 (Ar), 128.27 (Ar), 128.25 (Ar), 128.20 (Ar), 128.1 (Ar),
128.04 (2C, Ar), 128.01 (Ar), 127.91 (Ar), 127.86 (Ar), 127.71 (Ar),
127.67 (Ar), 127.66 (Ar), 127.63 (Ar), 127.53 (Ar), 127.51 (Ar), 127.46
(Ar), 127.39 (Ar), 127.37 (Ar), 127.2 (Ar), 114.2 (CH=CH2), 103.6 (C-1),
102.2 (C-1’), 100.1 (C-1’’’), 99.7 (C-1’’), 98.0 (C-1’’’’), 82.9 (C-3), 82.3
(C-2’), 81.9 (C-2), 79.4, 79.0 (C-3’, C-3’’’’), 77.2 (C-4’’’’), 76.6, 76.5,
76.4, 76.0, 75.3 (OCH2Ph), 75.14, 75.08, 74.95 (OCH2Ph), 74.93
(OCH2Ph), 74.8, 74.7 (OCH2Ph), 74.1 (OCH2Ph), 73.7, 73.6, 73.4, 73.2
(3ꢁOCH2Ph), 72.9, 72.4 (OCH2Ph), 71.7, 70.0, 69.9, 68.9, 68.4 (C-6, C-
6’, C-6’’, octenyl OCH2), 69.3, 67.9, 67.5 (C-5’’’’), 63.0 (C-6’’’), 57.5 (C-
2’’), 33.7, 29.7, 28.95, 28.86, 26.0 (5ꢁoctenyl CH2), 22.9 (NHAc),
16.7 ppm (C-6’’’’); HRMS (ESI): m/z [M+Na]+ calcd for
C103H123NNaO25: 1796.8276, found: 1796.8254.
H-2’), 3.28 (dd, J=9.6, 7.8 Hz, 1H, H-2’’’), 2.07–2.03 (m, 2H,
OCH2CH2(CH2)3CH2CH=CH2), 2.01 (s, 3H, NHAc), 1.63–1.59 (m, 2H,
OCH2CH2(CH2)3CH2CH=CH2),
1.41–1.30
(m,
6H,
OCH2CH2-
(CH2)3CH2CH=CH2), 1.16 ppm (d, J=6.6 Hz, 3H, H-6’’’’); 13C NMR
(126 MHz, D2O): d=175.7 (C=O), 141.3 (CH=CH2), 115.0 (CH=CH2),
103.9 (C-1), 103.5, 103.0, 102.8 (C-1’, C-1’’, C-1’’’), 99.6 (C-1’’’’), 83.1,
79.4, 76.1, 75.9, 75.8, 75.7 (2C), 75.4, 74.1, 73.8, 73.5, 72.9, 72.0,
71.7, 70.9, 70.2, 69.33, 69.28, 68.7, 67.7 (C-5’’’’), 62.5, 61.9, 61.1, 60.6
(C-6, C-6’, C-6’’, C-6’’’), 57.0 (C-2’’), 34.0 (octenyl CH2), 29.6 (octenyl
CH2), 29.0 (2C, octenyl CH2), 25.8 (octenyl CH2), 23.2 (NHAc),
16.3 ppm (C-6’’’’); HRMS (ESI): m/z [M+Na]+ calcd for
C40H69NNaO25: 986.4051, found: 986.4047.
8-[(2-Aminoethyl)thiol]-1-octyl b-d-galactopyranosyl-(1!4)-[a-l-
fucopyranosyl-(1!3)]-2-acetamido-2-deoxy-b-d-glucopyranosyl-
(1!3)-b-d-galactopyranosyl-(1!4)-b-d-glucopyranoside (15):
Compound 14 (38 mg, 0.039 mmol) and cysteamine hydrochloride
(44 mg, 0.39 mmol) were dissolved in dry MeOH (0.5 mL) in
a quartz tube. The solution was degassed and the tube was filled
with argon. After irradiation with UV light for 2.5 h, the solution
was concentrated and subjected to C18 chromatography using gra-
dient elution (0.5% aq AcOH!3:7 v/v MeOH/0.5% aq AcOH) to
afford the corresponding amine salt 15 (42 mg, quantitative).
[a]D =ꢀ41.1 (c=0.9, MeOH); 1H NMR (600 MHz, D2O): d=5.11 (d,
J=3.9 Hz, 1H, H-1’’’’), 4.83–4.80 (m, 1H, H-5’’’’), 4.70 (d, J=8.4 Hz,
1H, H-1’’), 4.46 (d, J=7.8 Hz, 1H, H-1’’’), 4.45 (d, J=7.8 Hz, 1H, H-
1’), 4.42 (d, J=7.8 Hz, 1H, H-1), 4.14 (d, J=2.9 Hz, 1H), 3.96–3.84
(m, 9H), 3.79–3.55 (m, 17H), 3.48 (dd, J=9.6, 7.8 Hz, 1H, H-2’),
3.29–3.26 (m, 1H, H-2’’’), 3.20 (t, J=6.7 Hz, 2H, SCH2CH2N), 2.83 (t,
J=6.7 Hz, 2H, SCH2CH2N), 2.58 (t, J=7.3 Hz, 2H, SCH2(CH2)6CH2O),
2.01 (s, 3H, NHAc), 1.63–1.56 (m, 4H, OCH2CH2(CH2)4CH2CH2S),
1.38–1.31 (m, 8H, OCH2CH2(CH2)4CH2CH2S), 1.16 ppm (d, J=6.6 Hz,
3H, H-6’’’’); 13C NMR (126 MHz, D2O): d=175.7 (C=O), 103.9 (C-1),
103.5, 103.0, 102.8 (C-1’, C-1’’, C-1’’’), 99.6 (C-1’’’’), 83.1, 79.4, 76.1,
75.90, 75.86, 75.7 (2C), 75.5, 74.1, 73.8, 73.5, 72.9, 72.0, 71.7, 70.9,
70.2, 69.34, 69.27, 68.7, 67.7 (C-5’’’’), 62.5, 61.9, 61.1, 60.6 (C-6, C-6’,
C-6’’, C-6’’’), 57.0 (C-2’’), 39.4 (SCH2CH2N), 31.7 (SCH2(CH2)6CH2O),
29.7 (SCH2(CH2)6CH2O), 29.5 (SCH2CH2N), 29.3, 29.1(2C), 28.8, 25.9
(5ꢁSCH2(CH2)6CH2O), 23.2 (NHAc), 16.3 ppm (C-6’’’’); HRMS (ESI):
m/z [M+H]+ calcd for C42H77N2O25S: 1041.4531, found: 1041.4517.
Preparation of HSA conjugate: Compound 1 (1.5 mg) was dis-
solved in DMF (15 mL) and injected into a solution of human serum
albumin (HSA; 1.5 mg) in phosphate buffer (0.3 mL, pH 7.5). The re-
action was left at RT for one day, and the mixture was dialyzed
against deionized H2O (5ꢁ4 L). A white solid was obtained after
lyophilization. The degree of incorporation of the pentasaccharide
into the glycoconjugate was determined to be 21 by MALDI-TOF
MS.
7-Octen-1-yl
b-d-galactopyranosyl-(1!4)-[a-l-fucopyranosyl-
(1!3)]-2-acetamido-2-deoxy-b-d-glucopyranosyl-(1!3)-b-d-ga-
lactopyranosyl-(1!4)-b-d-glucopyranoside (14): Sodium was
added to freshly collected liquid ammonia (~8 mL) at ꢀ788C until
the blue colour of the solution persisted. A solution of 13 (144 mg,
0.73 mmol) in THF (4 mL) and MeOH (30 mL) was added drop wise
at ꢀ788C. After 2 h, MeOH (5 mL) was added and the solution was
concentrated in vacuo to dryness. The residue was dissolved in
MeOH (30 mL), neutralized with Amberlite IR120 H+ ion-exchange
resin, filtered and concentrated. The crude residue was purified by
C18 chromatography using gradient elution (H2O!3:7 v/v MeOH/
H2O) to give 14 as a white solid (76 mg, 97%): [a]D =ꢀ45.6 (c=0.9,
Acknowledgement
Funding for this work was obtained via a Canadian Institutes of
Health Research (CIHR) team grant (RMF 92091), a Natural Scien-
ces and Engineering Research Council of Canada (NSERC)/CIHR
Collaborative Health Research Projects (CHRP) grant
(CHRPJ350946–08) and the Alberta Glycomics Centre (Canada).
Alberta Innovates—Technology Futures is gratefully acknowl-
edged for a scholarship to JZ.
1
MeOH); H NMR (600 MHz, D2O): d=5.91 (ddt, J=17.2, 10.4, 6.7 Hz,
1H, CH=CH2), 5.11 (d, J=4.0 Hz, 1H, H-1’’’’), 5.06–5.02 (m, 1H, CH=
CH2), 4.97–4.95 (m, 1H, CH=CH2), 4.82 (q, J=6.7 Hz, 1H, H-5’’’’),
4.70 (d, J=8.3 Hz, 1H, H-1’’), 4.46 (d, J=7.8 Hz, 1H, H-1’’’), 4.45 (d,
J=7.8 Hz, 1H, H-1’), 4.42 (d, J=7.8 Hz, 1H, H-1), 4.14 (d, J=3.5 Hz,
1H), 3.96–3.84 (m, 9H), 3.79–3.55 (m, 17H), 3.48 (dd, J=9.8, 7.8 Hz,
ꢀ 2013 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ChemistryOpen 2013, 2, 156 – 163 162

www.chemistryopen.org
[8] Y. Zhang, D. Dong, H. Qu, M. Sollogoub, Y. Zhang, Eur. J. Org. Chem.
2011, 2011, 7133–7139.
[9] C.-S. Chao, C.-W. Li, M.-C. Chen, S.-S. Chang, K.-K. T. Mong, Chem. Eur. J.
2009, 15, 10972–10982.
[10] Z. Zhang, I. R. Ollmann, X.-S. Ye, R. Wischnat, T. Baasov, C.-H. Wong, J.
Am. Chem. Soc. 1999, 121, 734–753.
[11] R. Johnsson, D. Olsson, U. Ellervik, J. Org. Chem. 2008, 73, 5226–5232.
[12] H. Cheng, X. Cao, M. Xian, L. Fang, T. B. Cai, J. J. Ji, J. B. Tunac, D. Sun,
P. G. Wang, J. Med. Chem. 2005, 48, 645–652.
Keywords: activated esters · immunomodulatory glycans ·
lacto-N-fucopentaose III (LNFPIII) · regioselective glycosylation ·
oligosaccharides
[1] A. I. Ko, U. C. Drꢃger, D. A. Harn, Proc. Natl. Acad. Sci. USA 1990, 87,
4159–4163.
[2] B. Stahl, S. Thurl, J. R. Zeng, M. Karas, F. Hillenkamp, M. Steup, G. Sa-
watzki, Anal. Biochem. 1994, 223, 218–226.
[13] U. Ellervik, G. Magnusson, J. Org. Chem. 1998, 63, 9314–9322.
[14] M. Guillemineau, F.-I. Auzanneau, Carbohydr. Res. 2012, 357, 132–138.
[15] K. Bock, C. Pedersen, J. Chem. Soc. Perkin Trans. 2 1974, 293.
[16] J. D. C. Codꢄe, R. E. J. N. Litjens, R. den Heeten, H. S. Overkleeft, J. H. van
Boom, G. A. van der Marel, Org. Lett. 2003, 5, 1519–1522.
[17] A. Dondoni, A. Massi, P. Nanni, A. Roda, Chem. Eur. J. 2009, 15, 11444–
11449.
[3] P. Dutta, D. A. Hullett, D. A. Roenneburg, J. R. Torrealba, H. W. Sollinger,
D. A. Harn, W. J. Burlingham, Transplantation 2010, 90, 1071–1078.
[4] G. J. Freeman, A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura,
L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byrne, H. F. Horton, L. Fouser,
L. Carter, V. Ling, M. R. Bowman, B. M. Carreno, M. Collins, C. R. Wood, T.
Honjo, J. Exp. Med. 2000, 192, 1027–1034.
[5] X. Fan, A. Ang, S. M. Pollock-BarZiv, A. I. Dipchand, P. Ruiz, G. Wilson,
J. L. Platt, L. J. West, Nat. Med. 2004, 10, 1227–1233.
[18] X. Wu, C.-C. Ling, D. R. Bundle, Org. Lett. 2004, 6, 4407–4410.
[6] A. M. Slaney, V. A. Wright, P. J. Meloncelli, K. D. Harris, L. J. West, T. L.
Lowary, J. M. Buriak, ACS Appl. Mater. Interfaces 2011, 3, 1601–1612.
[7] Y.-M. Zhang, J. Esnault, J.-M. Mallet, P. Sinay¨, J. Carbohydr. Chem. 1999,
18, 419–427.
Received: May 15, 2013
Published online on July 11, 2013
ꢀ 2013 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ChemistryOpen 2013, 2, 156 – 163 163